Prednisone + Jakavi(ruxolitinib) + Prednisone
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
GVHD - Graft-Versus-Host Disease
Conditions
GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation
Trial Timeline
Jan 15, 2025 → Aug 31, 2029
NCT ID
NCT06756061About Prednisone + Jakavi(ruxolitinib) + Prednisone
Prednisone + Jakavi(ruxolitinib) + Prednisone is a phase 2 stage product being developed by Novartis for GVHD - Graft-Versus-Host Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06756061. Target conditions include GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06756061 | Phase 2 | Recruiting |
Competing Products
19 competing products in GVHD - Graft-Versus-Host Disease